News & Updates

Histologic margin status shows a robust association with progression for lentigo maligna melanoma, suggest the results of a recent study.

Use of niraparib appears to contribute to a higher risk of haematological toxicities as compared with olaparib, suggests a study. The most common haematological adverse event is anaemia.

Clinical trials on first-line therapies for advanced or metastatic nonsmall cell lung cancer (NSCLC) from 2010 to 2020 have reported better survival and a steady improvement in quality of life (QoL) among patients, according to the results of a systematic review.

Use of behavioural interventions, specifically multicomponent and patient navigation interventions, helps increase the uptake of colonoscopy for colorectal cancer (CRC) screening, reveals a study.

Adding percent free prostate-specific antigen (PSA) to total PSA results in better prediction of clinically significant prostate cancer and fatal prostate cancer in men, reports a study.

In the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC) harbouring EGFR mutation, the combination of osimertinib plus pemetrexed and platinum-based chemotherapy outperformed osimertinib alone in terms of extending progression-free survival (PFS), according to the interim results of the phase III FLAURA2 trial presented at WCLC 2023.